1647– Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma

Page last updated: 11 October 2023

Application Detail

Description of Medical Service

Brexucabtagene autoleucel is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapeutic process, involving harvesting, modifying, expanding and re-infusing a patient's own immune T-cells, to target and destroy certain cancerous cells.

Description of Medical Condition

Relapsed or refractory mantle cell lymphoma is an aggressive subtype of non-Hodgkin lymphoma

Reason for Application

Highly Specialised Therapy - National Health Reform Agreement

Medical Service Type

Therapeutic technology

Previous Application Number/s

Not Applicable

Associated Documentation

Application Form

Application Form (PDF 1088 KB)
Application Form (Word 345 KB)

Consultation Survey

Consultation Survey (PDF 559 KB)
Consultation Survey (Word 71 KB)

PICO Confirmation


Assessment Report


Public Summary Document

Public Summary Document (PDF 929 KB)
Public Summary Document (Word 531 KB)

Meetings for this Application


Expedited – Bypassing PASC


10-11 June 2021


29-30 July 2021
29 July 2023